The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases

Orphanet Journal of Rare Diseases

Janbernd Kirschner²  Rudolf Korinthenberg²  Volker Straub¹  Kate Bushby¹  Kirsten König²  Kathrin Gramsch²  Adrian Tassoni²  Hanns Lochmüller¹  Sunil Rodger¹ 

[1] Institute of Genetic Medicine, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne NE1 3BZ, UK;Department of Neuropaediatrics and Muscle Disorders, University Medical Center Freiburg, Mathildenstrasse 1, 79106, Freiburg, Germany

关键词: CARE-NMD;    ERN;    Reference networks;    CTSR;    Centres of expertise;    Care sites;    Trial sites;    Clinical trials;    Registries;    Rare diseases;   

Others  :  863444
DOI  :  10.1186/1750-1172-8-171

 received in 2013-08-16, accepted in 2013-10-16,  发布年份 2013

【 摘 要 】

Background

Rare diseases pose many research challenges specific to their scarcity. Advances in potential therapies have made it more important than ever to be able to adequately identify not only patients with particular genotypes (via patient registries) but also the medical professionals who provide care for them at particular specialist centres of expertise and who may be competent to participate in trials. Work within the neuromuscular field provides an example of how this may be achieved.

Methods

This paper describes the development of the TREAT-NMD Care and Trial Site Registry (CTSR), an initiative of an EU-funded Network of Excellence, and its utility in providing an infrastructure for clinical trial feasibility, recruitment, and other studies.

Results

285 CTSR-registered centres, reporting 35,495 neuromuscular patients, are described alongside an analysis of their provision for DMD. Site characteristics vary by country: the average number of DMD patients seen per site in the United States (96) is more than in Germany (25), and paediatric/adult breakdown is also markedly distinct. Over 70% of sites have previous trial experience, with a majority including a Clinical Trials Unit. Most sites also have MLPA diagnostic capability and access to a range of medical specialists. However, in the three countries reporting most sites (US, the UK and Germany), few had access to all core DMD specialists internally. Over 60% of sites did not report any form of transition arrangement.

Conclusions

Registries of care and trial sites have significant utility for research into rare conditions such as neuromuscular diseases, demonstrated by the significant engagement by industry and other researchers with the CTSR. We suggest that this approach may be applicable to other fields needing to identify centres of expertise with the potential to carry out clinical research and engage in clinical trials. Such registries also lend themselves to the developing context of European Reference Networks (ERNs), which seek to build networks of centres of expertise which fit specific criteria, and which may themselves aid the sustainability of such registries. This is particularly the case given the utility of registries such as the CTSR in enabling networks of best-practice care centres.

【 授权许可】

   
2013 Rodger et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]COM(2008) 679 Final: Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on Rare Diseases: Europe’s Challenges [http://ec.europa.eu/health/ph_threats/non_com/docs/rare_com_en.pdf webcite]
• [2]TREAT-NMD [http://www.treat-nmd.eu/ webcite]
• [3]Taruscio D, Gainotti S, Vittozzi L, Bianchi F, Ensini M, Posada M: EPIRARE survey on activities and needs of rare disease registries in the European Union. Orphanet J Rare Dis 2012, 7:A22. BioMed Central Full Text
• [4]Rare disease registries in Europe, January 2013, Orphanet report series [http://www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf webcite]
• [5]The Parkinson Study Group [http://www.parkinson-study-group.org webcite]
• [6]European Cystic Fibrosis Society [http://www.ecfs.eu webcite]
• [7]European Huntington’s Disease Network [http://www.euro-hd.net webcite]
• [8]Dubowitz Neuromuscular Centre: Conditions we treat [http://www.gosh.nhs.uk/health-professionals/clinical-specialties/neuromuscular-information-for-health-professionals/conditions-we-treat/ webcite]
• [9]EUCERD Recommendations on Quality Criteria for Centres of Expertise for Rare Diseases in Member States, 24th October 2011 [http://www.EUCERD.eu/upload/file/EUCERDRecommendationCE.pdf webcite]
• [10]Muscular Dystrophy Campaign [http://www.muscular-dystrophy.org webcite]
• [11]CARE-NMD [http://www.care-nmd.eu/ webcite]
• [12]Care and Trial Site Registry (CTSR) [https://zks-internet.ukl.uni-freiburg.de/ctsr webcite]
• [13]Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, et al.: Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010, 9:77-93.
• [14]Abbott D, Carpenter J, Bushby K: Transition to adulthood for young men with Duchenne muscular dystrophy: research from the UK. Neuromuscul Disord 2012, 22:445-446.
• [15]North Star Clinical Network [http://www.muscular-dystrophy.org/how_we_help_you/for_professionals/clinical_databases webcite]
• [16]Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, et al.: Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010, 9:177-189.
• [17]British Myology Society [http://www.cnmd.ac.uk/partners/BMS webcite]
• [18]Bladen CL, Rafferty K, Straub V, Monges S, Moresco A, Dawkins H, Roy A, Chamova T, Guergueltcheva V, Korngut L, et al.: The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia. Hum Mutat 2013, 34:1449-1457.
• [19]Tuffery-Giraud S, Beroud C, Leturcq F, Yaou RB, Hamroun D, Michel-Calemard L, Moizard MP, Bernard R, Cossee M, Boisseau P, et al.: Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum Mutat 2009, 30:934-945.
• [20]Orphanet expert centres database [http://www.orpha.net/consor/cgi-bin/Clinics_Search.php?lng?=?EN webcite]
• [21]Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen G-J, den Dunnen JT: Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009, 30:293-299.
• [22]Norwood FLM, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V: Prevalence of genetic muscle disease in northern england: in-depth analysis of a muscle clinic population. Brain 2009, 132:3175-3186.
• [23]Scully MA, Cwik VA, Marshall BC, Ciafaloni E, Wolff JM, Getchius TS, Griggs RC: Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data? Neurol 2013, 80:583-589.
• [24]NeurOmics [http://www.rd-neuromics.eu/ webcite]